You are here » Home » Companies » Company Overview » Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd.

BSE: 532637 Sector: Health care
NSE: MANGALAM ISIN Code: INE584F01014
BSE 00:00 | 14 Aug 101.80 -2.15
(-2.07%)
OPEN

109.60

HIGH

109.60

LOW

99.40

NSE 00:00 | 14 Aug 101.20 -4.10
(-3.89%)
OPEN

106.90

HIGH

106.90

LOW

99.50

OPEN 109.60
PREVIOUS CLOSE 103.95
VOLUME 13510
52-Week high 225.90
52-Week low 68.55
P/E 8.10
Mkt Cap.(Rs cr) 161
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 109.60
CLOSE 103.95
VOLUME 13510
52-Week high 225.90
52-Week low 68.55
P/E 8.10
Mkt Cap.(Rs cr) 161
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Mangalam Drugs and Organics Ltd. (MANGALAM) - Company History

Mangalam Drugs and Organics Ltd is an India-based company. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra. They also have an in-house Research and Development (R&D) Base. Their products include chloroquine phosphate I.P., aluminum chloride anhydrous, and dyes and intermediaries. Mangalam Drugs and Organics Ltd was incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. The company was promoted by Dhoot family. The company was established with a view to set up a plant for manufacture of organic and inorganic chemicals. In April 1, 1996 three other group companies, namely Mangalam Organics Pvt Ltd, Shree Mangalam Pharma Pvt Ltd and Mangalam Rasayan Pvt Ltd were amalgamated with the company. In July 1, 1997, the company changed their name from Advent Pharma Pvt Ltd to Mangalam Drugs and Organics Pvt Ltd. In September 22, 1997, the company was converted into a deemed public company and word 'private' was deleted from the company's name. In the year 1999, the company launched a new product namely, Nimesulide. In the year 2001, they launched two new products namely Amodiaquine Hydrochloride and Amodiaquine. In August 10, 2001, the company was converted into a full fledged public limited company. In the year 2003-2004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During the 2004-05, the capacity is being further enhanced to 960 MTPA. During the year 2005-06, the company further enhanced their Bulk drug production capacity from 960 MT per annum to 1260 MT per annum. During the year 2007-08, the company developed and introduced new bulk drugs namely Bisoprolol Fumarate and Pantaprazole Sodium. Also, they increased the production capacity of Meta Chloro Aniline & Allied Products from 250 tons to 350 tons. During the year 2009-10, the company in addition to Regulatory Affairs Cell established Intellectual Property Rights (IPR) cell. The regulatory affairs cell submitted 6 DMFs to WHO-Geneva out of which 2 DMFs corresponding to Artemether and Lumefantrine had been approved.